Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy

[1]  P. Vávra,et al.  A narrative review on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis versus hepatocellular carcinoma: do you mind? , 2022, Revista da Associacao Medica Brasileira.

[2]  P. Vávra,et al.  Hepatocellular carcinoma versus nonalcoholic fatty liver disease: metabolic, environmental, and genetic association? De facto? , 2022, Revista da Associacao Medica Brasileira.

[3]  D. Sengul,et al.  Connection of reactive oxygen species as an essential actor for the mechanism of phenomena; ischemic preconditioning and postconditioning: Come to age or ripening? , 2021, Northern clinics of Istanbul.

[4]  S. Kwiatkowski,et al.  Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points , 2021, Cancers.

[5]  Ahmed Rebai,et al.  Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer , 2021, Scientific Reports.

[6]  G. Martinelli,et al.  Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy , 2021, Cancers.

[7]  E. Darai,et al.  PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases , 2021, European journal of histochemistry : EJH.

[8]  J. Ledermann,et al.  Immune checkpoint inhibitors in ovarian cancer: where do we stand? , 2021, Therapeutic advances in medical oncology.

[9]  Yang Ding,et al.  Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma , 2020, World journal of gastrointestinal oncology.

[10]  C. Solinas,et al.  Programmed Cell Death-Ligand 2: A Neglected But Important Target in the Immune Response to Cancer? , 2020, Translational oncology.

[11]  Zhou Wang,et al.  A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. , 2019, Cell reports.

[12]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Y. Nishimura,et al.  Possible Biomarkers for Cancer Immunotherapy , 2019, Cancers.

[14]  P. Validire,et al.  Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth , 2019, Cancer Immunology Research.

[15]  P. Bankhead,et al.  Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells , 2019, Front. Immunol..

[16]  Y. Maehara,et al.  Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients , 2019, Annals of Surgical Oncology.

[17]  Li Wu,et al.  PD-1/PD-L1 Inhibitors in Cervical Cancer , 2019, Front. Pharmacol..

[18]  Ni Zhang,et al.  Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. , 2019, Immunotherapy.

[19]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[20]  Sladjana Vujacic.  IDENTIFICATION OF NEW MOLECULAR BIOMARKERS - PROTEOMICS , 2018 .

[21]  C. Shao,et al.  Lessons learned from the blockade of immune checkpoints in cancer immunotherapy , 2018, Journal of Hematology & Oncology.

[22]  Darrell J Irvine,et al.  Roles for Innate Immunity in Combination Immunotherapies. , 2017, Cancer research.

[23]  K. Haas,et al.  PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5–Dependent Mechanism , 2017, The Journal of Immunology.

[24]  J. Lunceford,et al.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer , 2017, Clinical Cancer Research.

[25]  M. Garg,et al.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..

[26]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[27]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Su-Jin Shin,et al.  Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status , 2016, Annals of Surgical Oncology.

[29]  V. Boussiotis,et al.  Biochemical Signaling of PD-1 on T Cells and Its Functional Implications , 2014, Cancer journal.

[30]  Loise M. Francisco,et al.  RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance , 2014, The Journal of experimental medicine.

[31]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[32]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[33]  S. Ferrini,et al.  NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. , 2009, International immunology.

[34]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[35]  Yongliang Zhang,et al.  Regulation of T cell activation and tolerance by PDL2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Omura,et al.  Preferential contribution of B7‐H1 to programmed death‐1‐mediated regulation of hapten‐specific allergic inflammatory responses , 2003, European journal of immunology.

[37]  O. Majdic,et al.  B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy 1 , 2003, The Journal of Immunology.

[38]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.